This latest of technologies analyzes fetal genetic material in the mother's blood in order to determine the possibility that the fetus may have one of 3 specific genetic abnormalities, namely trisomy 21 (Down Syndrome), trisomy 18 and trisomy 13. Using NIPT makes available to select high risk patients safe and effective non-invasive testing for trisomies with accuracies of >99% for trisomy 21, and >97% for trisomy 18. In addition, this test is very unlikely to give an erroneous concerning result: this can happen in less than 0.1% of cases. That means that NIPT provides high diagnostic accuracy while avoiding unnecessary invasive testing, such as a CVS or an amniocentesis, since invasive testing may lead to miscarriage.

Patients need to discuss the benefits and limitations of NIPT with their health care provider in order to decide if this may be a suitable test for them. If we may provide you with any further clarifications, please contact CFAFC at +96170236648 or send an email to